LDR-brachytherapy with I-125-seeds for prostate cancer - Offenburg results: a retrospective analysis of 260 patients

LDR-brachytherapy with I-125-seeds for prostate cancer - Offenburg results: a retrospective analysis of 260 patients - LDR-BT-OG

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016919

Enrollment

260

Registered

2019-04-11

Start date

2019-04-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Data Evaluation of patients treated with brachytherapy for prostate cancer in Offenburg from 2002-2017

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: RETROSPECTIVE: LDR-brachytherapy (Low dose rate) for prostate cancer in Offenburg in the time from 2002 to 2017

Exclusion criteria

Exclusion criteria: treatment after 09/2015

Design outcomes

Primary

Measure	Time frame
Biochemical recurrence (PSA); results of laboratory analysis in patients' records before brachytherapy and in follow-up	—

Secondary

Measure	Time frame
Side effects documented in patients' records, CTC Score (Common toxicity Criteria)	—

Countries

Germany

Contacts

Public ContactFelix Momm

Ortenau-Klinikum Offenburg-Kehl, Standort St. Josefsklinik

radioonkologie.og@ortenau-klinikum.de++49-781-472-3201

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026